Velan Capital Investment Management LP
An institutional investment manager in ALPHARETTA, GA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1848809.
- Reported value$164.2m
- Positions51
Holdings: 51 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31. The filing's table has 53 lines; lines for the same security and option type are added together here.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 29.7 | 18.1% | 88,781 | Reduced−12,000 | |
| Maplight Therapeutics IncMPLT | COM | 56565P103 | 17.7 | 10.8% | 492,893 | Unchanged | |
| Sutro Biopharma IncSTRO | COM SHS | 869367201 | 17.0 | 10.4% | 512,160 | Unchanged | |
| Immix Biopharma IncIMMX | COM | 45258H106 | 11.2 | 6.8% | 1,085,000 | Added+345,000 | |
| Protara Therapeutics IncTARA | COM STK | 74365U107 | 10.9 | 6.6% | 2,844,652 | Added+10,000 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 8.7 | 5.3% | 65,630 | Reduced−11,370 | |
| Tenax Therapeutics IncTENX | COM NEW | 88032L605 | 8.0 | 4.9% | 549,985 | Reduced−33,348 | |
| Anteris Technologies GlobalAVR | COM | 03675P102 | 6.9 | 4.2% | 700,000 | Unchanged | |
| Edesa Biotech IncEDSA | COM NEW | 27966L306 | 6.7 | 4.1% | 827,500 | Unchanged | |
| Evommune IncEVMN | COM SHS | 30054Y107 | 6.0 | 3.7% | 451,255 | Added+5,000 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 6.0 | 3.7% | 324,452 | Added+139,330 | |
| Xencor IncXNCR | COM | 98401F105 | 4.1 | 2.5% | 255,000 | Added+5,000 | |
| Rezolute IncRZLT | COM NEW | 76200L309 | 3.9 | 2.4% | 750,000 | Unchanged | |
| Heron Therapeutics IncHRTX | COM | 427746102 | 3.7 | 2.3% | 8,753,290 | Unchanged | |
| Verrica Pharmaceuticals IncVRCA | COM SHS | 92511W207 | 2.9 | 1.8% | 471,559 | Unchanged | |
| C4 Therapeutics IncCCCC | COM STK | 12529R107 | 2.7 | 1.6% | 570,000 | New+570,000 | |
| Eupraxia Pharmaceuticals IncEPRX | COM | 29842P105 | 2.3 | 1.4% | 352,000 | Unchanged | |
| Adma Biologics IncADMA | COM | 000899104 | 2.1 | 1.3% | 250,000 | New+250,000 | |
| Rein Therapeutics IncRNTX | COM NEW | 00887A204 | 1.8 | 1.1% | 1,700,000 | New+1,700,000 | |
| Lyell Immunopharma IncLYEL | COM NEW | 55083R203 | 1.5 | 0.9% | 105,000 | Added+3,000 | |
| Nasus Pharma Ltd | ORD SHS | M7071P109 | 1.3 | 0.8% | 359,390 | Unchanged | |
| Profound Med CorpPROF | COM NEW | 74319B502 | 1.1 | 0.7% | 170,278 | Reduced−115,432 | |
| Jasper Therapeutics IncJSPR | COM NEW | 471871202 | 1.1 | 0.7% | 2,668,395 | Unchanged | |
| Tenax Therapeutics IncTENX | COM NEW | 88032L605 | 1.0 | 0.6% | 68,700 | Call | New+68,700 |
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 0.5 | 0.3% | 3,700 | Unchanged | |
| Cytomx Therapeutics Inc.CTMX | COM | 23284F105 | 0.5 | 0.3% | 120,000 | Reduced−420,000 | |
| Neumora Therapeutics Inc.NMRA | COM | 640979100 | 0.4 | 0.2% | 230,000 | Added+150,000 | |
| Nurix Therapeutics IncNRIX | COM | 67080M103 | 0.4 | 0.2% | 16,000 | Unchanged | |
| Ovid Therapeutics IncOVID | COM | 690469101 | 0.3 | 0.2% | 130,000 | Reduced−30,000 | |
| Precision Biosciences IncDTIL | COM NEW | 74019P207 | 0.3 | 0.2% | 40,000 | Unchanged | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 0.3 | 0.2% | 11,000 | Unchanged | |
| Macrogenics IncMGNX | COM | 556099109 | 0.3 | 0.2% | 60,000 | Added+30,000 | |
| Corbus Pharmaceuticals HoldingsCRBP | COM NEW | 21833P301 | 0.2 | 0.1% | 26,000 | Unchanged | |
| Artiva Biotherapeutics IncARTV | COM | 04317A107 | 0.2 | 0.1% | 25,000 | Unchanged | |
| Replimune Group IncREPL | COM | 76029N106 | 0.2 | 0.1% | 20,000 | Unchanged | |
| Syndax Pharmaceuticals IncSNDX | COM | 87164F105 | 0.2 | 0.1% | 10,000 | Unchanged | |
| Immunome IncIMNM | COM | 45257U108 | 0.2 | 0.1% | 10,000 | Unchanged | |
| Tectonic Therapeutic IncTECX | COM | 878972108 | 0.2 | 0.1% | 6,000 | New+6,000 | |
| Rocket Pharmaceuticals IncRCKT | COM | 77313F106 | 0.2 | 0.1% | 60,000 | Reduced−234,643 | |
| Karyopharm Therapeutics IncKPTI | COM NEW | 48576U205 | 0.2 | 0.1% | 20,000 | Added+5,000 | |
| AN2 Therapeutics IncANTX | COM | 037326105 | 0.2 | 0.1% | 40,000 | New+40,000 | |
| Viridian Therapeutics IncVRDN | COM | 92790C104 | 0.2 | 0.1% | 10,000 | Reduced−81,123 | |
| Scynexis IncSCYX | COM | 811292309 | 0.2 | <0.1% | 40,000 | New+40,000 | |
| Quoin Pharmaceuticals LtdQNRX | SPONSORED ADS | 74907L409 | 0.2 | <0.1% | 32,372 | Reduced−52,477 | |
| Xilio Therapeutics IncXLO | COM | 98422T209 | 0.1 | <0.1% | 14,285 | Unchanged | |
| Inspiremd IncNSPR | COM | 45779A846 | 0.1 | <0.1% | 148,138 | Reduced−1,951,514 | |
| Kalaris Therapeutics IncKLRS | COM | 482929106 | 0.1 | <0.1% | 25,000 | Added+7,000 | |
| Larimar Therapeutics IncLRMR | COM | 517125100 | 0.1 | <0.1% | 33,000 | Unchanged | |
| Proqr Thrapeutics N V | SHS EURO | N71542109 | 0.1 | <0.1% | 45,000 | Unchanged | |
| Context Therapeutics IncCNTX | COM | 21077P108 | 0.0 | <0.1% | 59,700 | Reduced−40,300 | |
| Gossamer Bio Inc | COM | 38341P102 | 0.0 | <0.1% | 70,000 | Unchanged |
Sold out: 5 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals inARWR | COM | 04280A100 | 0.0 | 0.0% | 0 | Sold out−6,500 | |
| Design Therapeutics IncDSGN | COM | 25056L103 | 0.0 | 0.0% | 0 | Sold out−20,000 | |
| Esperion Therapeutics Inc Ne | COM | 29664W105 | 0.0 | 0.0% | 0 | Sold out−1,720,000 | |
| Kazia Therapeutics LtdKZIA | SPONSORED ADS | 48669G303 | 0.0 | 0.0% | 0 | Sold out−135,315 | |
| PMV Pharmaceuticals IncPMVP | COM | 69353Y103 | 0.0 | 0.0% | 0 | Sold out−73,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001848809-26-000003 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.